Annovis Bio Advances Alzheimer's Trial, Burns Cash at Accelerated Rate
Event summary
- Annovis initiated a pivotal Phase 3 clinical trial in February 2025 for its oral therapy, buntanetap, targeting early Alzheimer's disease.
- The company has enrolled 65% of the target participant population (approximately 200 participants) across 83 clinical sites in the US as of March 2026.
- Research and development expenses increased to $25.2 million in 2025, compared to $20.0 million in 2024.
- Annovis reported a net loss of $28.8 million for the fiscal year 2025, with cash and cash equivalents totaling $19.5 million as of December 31, 2025, sufficient to fund operations into Q3 2026.
- The company transferred patents for a new crystal form of buntanetap, extending IP protection until 2047.
The big picture
Annovis is betting heavily on buntanetap's ability to address multiple neurodegenerative pathways, a strategy that, if successful, could yield a blockbuster drug. However, the company's accelerated cash burn and reliance on clinical trial success create significant execution risk. The Phase 3 Alzheimer's trial represents a pivotal moment, and its outcome will largely determine the company's future trajectory.
What we're watching
- Enrollment Pace
- The speed of patient enrollment in the Phase 3 trial will be critical; a slowdown could delay data readouts and impact investor confidence, given the current 65% completion rate.
- Cash Runway
- Annovis's current cash runway extends only to the third quarter of 2026, necessitating further financing rounds or a successful partnership to support continued development.
- Regulatory Approval
- The FDA's feedback on the potential Parkinson's disease dementia study will dictate the timeline and design of future trials, influencing the overall development pathway for buntanetap.
Related topics